公开(公告)号：US20240360215A1

公开(公告)日：2024-10-31

申请号：US18645760

申请日：2024-04-25

Applicant: The Regents of the University of California

Inventor： James L. Rubenstein

IPC: C07K16/28 ,  A61K9/00 ,  A61K31/454 ,  A61K31/519 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K9/0019 ,  A61K31/454 ,  A61K31/519 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24

Abstract: The disclosure provides a method of treating CNS lymphomas using a combination therapy comprising an anti-CD19 antibody and an immunomodulatory imide drug.

公开(公告)号：US20240358807A1

公开(公告)日：2024-10-31

申请号：US18489222

申请日：2023-10-18

Applicant: Cognate Bioservices, Inc. ,  Northwest Biotherapeutics, Inc. ,  The Regents of the University of California ,  RevImmune, Inc.

Inventor： Marnix Leo Bosch ,  James Kelly Ganjei ,  Linda F. Powers ,  Linda M. Liau ,  Robert M. Prins

IPC: A61K39/00 ,  A61F7/00 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  C07K16/28

CPC classification number: A61K39/0011 ,  A61F7/00 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61K38/2046 ,  A61K38/2086 ,  A61K39/39 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61N5/10 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/55527

Abstract: A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.

公开(公告)号：US20240358804A1

公开(公告)日：2024-10-31

申请号：US18397180

申请日：2023-12-27

Applicant: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER ,  THE UNIVERSITY OF UTAH

Inventor： Ashraf S. IBRAHIM ,  June L. ROUND ,  Kyla OST

IPC: A61K39/00 ,  A61K9/00 ,  A61P1/00

CPC classification number: A61K39/0002 ,  A61K9/0019 ,  A61K9/0073 ,  A61P1/00 ,  A61K2039/545

Abstract: The invention provides a vaccine against inflammatory bowel disease (IBD), such as Crohn's disease, ulcerative colitis, and the like. The vaccine comprises a polypeptide comprising a Candida adhesin antigen, typically an isolated agglutinin-like sequence (Als) protein antigen, formulated with one or more pharmaceutically acceptable carriers or excipients.

公开(公告)号：US20240352153A1

公开(公告)日：2024-10-24

申请号：US18291128

申请日：2022-07-22

Applicant: Akeso Biopharma, Inc ,  AKESO PHARMACEUTICALS, INC.

Inventor： Zhongmin WANG ,  Baiyong LI ,  Yu XIA

IPC: C07K16/46 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/46 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/507 ,  A61K2039/545

Abstract: A pharmaceutical composition comprising an anti-TIGIT antibody or an antigen-binding fragment thereof, and an anti-CTLA4-anti-PD-1 bispecific antibody or an antigen-binding fragment thereof. Specifically, a heavy chain variable region of the antibody contains HCDR1-HCDR3 having amino acid sequences as shown in SEQ ID NOs: 3-5, respectively, and a light chain variable region contains LCDR1-LCDR3 having amino acid sequences as shown in SEQ ID NOs: 8-10, respectively.

公开(公告)号：US20240352133A1

公开(公告)日：2024-10-24

申请号：US18749821

申请日：2024-06-21

Applicant: Viridian Therapeutics, Inc.

Inventor： Vahe BEDIAN ,  Yang ZHAO

IPC: C07K16/28 ,  A61K33/04 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P27/02 ,  C07K16/24

CPC classification number: C07K16/2863 ,  A61K33/04 ,  A61K39/3955 ,  A61K45/06 ,  A61P27/02 ,  C07K16/241 ,  C07K16/248 ,  C07K16/2887 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/622

Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.

公开(公告)号：US20240350611A1

公开(公告)日：2024-10-24

申请号：US18292237

申请日：2022-07-28

Applicant: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA

Inventor： Iris VALDES PRADO ,  Lázaro GIL GONZÁLEZ ,  Laura LAZO VAZQUEZ ,  Lisset HERMIDA CRUZ ,  Gerardo Enrique GUILLEN NIETO ,  Karem COBAS ACOSTA ,  Yaremis ROMERO FERNÁNDEZ ,  Andy Jesús BRUNO DARDER ,  Edith SUZARTE PORTAL ,  Yusleidi de la Caridad PÉREZ FUENTES

IPC: A61K39/12 ,  A61K39/00 ,  A61P37/04 ,  C07K14/005

CPC classification number: A61K39/12 ,  A61P37/04 ,  C07K14/005 ,  A61K2039/545 ,  A61K2039/55505

Abstract: Recombinant chimeric antigen containing a polypeptide comprises amino acids 2 to 104 of the zika virus capsid protein or a polypeptide with an amino acid sequence with at least 90% identity with such capsid protein region. Vaccine composition that comprises such recombinant chimeric antigen and a pharmaceutically approved adjuvant. Use of the recombinant chimeric antigen containing a polypeptide comprises amino acids 2 to 104 of the zika virus capsid protein or a polypeptide with an amino acid sequence with at least 90% identity with such capsid protein region, for manufacturing a medicament for the induction of immune response against zika virus. The invention revels also a method for the induction of immune response against zika virus wherein this recombinant chimeric antigen is administered.

公开(公告)号：US20240350528A1

公开(公告)日：2024-10-24

申请号：US18493604

申请日：2023-10-24

Applicant: HiberCell, Inc.

Inventor： Nandita Bose ,  Keith Gorden ,  Anissa SH. Chan ,  Steven Leonardo ,  Jeremy Graff ,  Xiaohong Qiu ,  Takashi Kangas ,  Kathryn A. Fraser ,  Adria Bykowski Jonas ,  Nadine Ottoson ,  Ross Fulton

IPC: A61K31/716 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44 ,  A61K39/00

CPC classification number: A61K31/716 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/22 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/44 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/73

Abstract: The present invention relates to the combination of soluble β-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble β-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

公开(公告)号：US12121755B2

公开(公告)日：2024-10-22

申请号：US18501741

申请日：2023-11-03

Applicant: DEKA BIOSCIENCES, INC.

Inventor： John Mumm

IPC: C07K14/54 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  A61P37/06 ,  C07K14/55 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46

CPC classification number: C07K14/5428 ,  A61P35/00 ,  A61P37/06 ,  C07K14/5406 ,  C07K14/55 ,  C07K16/10 ,  C07K16/1045 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/464 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/30

Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

公开(公告)号：US20240343812A1

公开(公告)日：2024-10-17

申请号：US18391233

申请日：2023-12-20

Applicant: Viridian Therapeutics, Inc.

Inventor： Denis O'Shaughnessy ,  Barrett Katz

IPC: C07K16/28 ,  A61K39/00 ,  A61P5/14 ,  A61P27/02 ,  A61P37/00

CPC classification number: C07K16/2863 ,  A61P5/14 ,  A61P27/02 ,  A61P37/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.

公开(公告)号：US20240343807A1

公开(公告)日：2024-10-17

申请号：US18292655

申请日：2022-08-05

Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Inventor： Xiquan ZHANG ,  Xunqiang WANG ,  Ding YU

IPC: C07K16/28 ,  A61K31/4709 ,  A61K31/555 ,  A61K31/7048 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2827 ,  A61K31/4709 ,  A61K31/555 ,  A61K31/7048 ,  A61P35/00 ,  A61K2039/505 ,  A61K2039/545

Abstract: Provided is a pharmaceutical composition for treating small cell lung cancer, which comprises an anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and a chemotherapeutic drug. Further provided is the use of the pharmaceutical composition or a kit containing the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof and the chemotherapeutic drug in the preparation of a drug for treating small cell lung cancer. Further provided is a method for treating small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and the chemotherapeutic drug.